340B PATIENTS Act of 2025

HR4581, introduced July 22, 2025, and referred to the House Energy and Commerce Committee, is a procedural bill that would codify existing 340B contract pharmacy relationships. The bill explicitly finds that covered entities have always used contract pharmacies and that manufacturers cannot place conditions on discount pricing based on dispensing location. This is a defensive measure protecting the status quo for hospitals, clinics, and their pharmacy partners. The bill authorizes zero new funding. It does not appropriate money, create tax credits, or establish new programs. It simply affirms existing administrative practice under the 340B statute. Because no money changes hands and no new obligations are imposed on any party, the economic impact is nil. Retail pharmacy chains like CVS ($CVS) and drug wholesalers like McKesson ($MCK) and Cardinal Health ($CAH) would see their existing 340B contract pharmacy revenue streams protected if the bill passed, but as a legislative matter, this bill is dead in the 119th Congress. It has not moved from committee in 9 months, has no hearings scheduled, and lacks leadership sponsorship (sponsor Rep. Matsui is a junior member with no committee chair). The companion bill S2372 faces the same fate in the Senate. Real market data shows $CVS up 16.51% over 30 days to $83.68, but this rally is attributable to broader market trends and sector rotation into value/healthcare, not this bill. $MCK (-7.05% 30-day) and $CAH (-10.53% 30-day) have both declined, confirming no bill-driven catalyst exists. No causal chain can be drawn from this legislation to any company's stock performance.